MONTEREY, Calif. — Suspension of treatment may be reasonable in selected patients with advanced wet age-related macular degeneration and low vision who are poor responders to anti-VEGF injections, according to a study.
“Due to the exclusion of these eyes from the pivotal clinical trials, it is unclear whether continuing treatment is necessary or effective,” and “there is little data on the safety of this practice,” Katherine Awh, BA, wrote in a poster presented at the Women in Ophthalmology 2022 Summer Symposium.
The study consisted of a retrospective chart review